Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
| ▸ | CCR4 | P51679 | 6/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.41 |
| ▸ | HTR3B | O95264 | 4/20 | 0.41 |
| ▸ | HTR3A | P46098 | 4/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053683 | 1.00 | SOS1 (0.48) | SOS1CCR4ADRB1HTR3EHTR3B | |
| SCHEMBL14995051 | 0.87 | CCR4 (0.42) | CCR4 | |
| SCHEMBL20130985 | 0.87 | CCR4 (0.42) | CCR4 | |
| SCHEMBL14995052 | 0.87 | CCR4 (0.42) | CCR4 | |
| SCHEMBL15053400 | 0.86 | SOS1 (0.41) | SOS1CCR4KMO | |
| SCHEMBL14994962 | 0.86 | SOS1 (0.41) | SOS1CCR4KMO | |
| SCHEMBL27978185 | 0.86 | SOS1 (0.41) | SOS1CCR4KMO | |
| SCHEMBL19373594 | 0.85 | KMO (0.40) | SOS1CCR4KMO | |
| SCHEMBL15692597 | 0.84 | CCR4 (0.42) | SOS1CCR4KMO | |
| SCHEMBL27978187 | 0.84 | CCR4 (0.39) | SOS1CCR4KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9790204-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2785710-B1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160185756-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9150550-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| CN-103974950-A | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX INC | 2014-08-06 | — | — | CN | disclosed |
| US-20140121195-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20130165423-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165423-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | SOS1 4244/4885CCR4 1/4885ADRB1 439/4885 |
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | SOS1 4244/4885CCR4 1/4885ADRB1 439/4885 |
| US-20160185756-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | SOS1 4244/4885CCR4 1/4885ADRB1 439/4885 |
| US-20140121195-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | SOS1 4244/4885CCR4 1/4885ADRB1 439/4885 |
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CCR4, CCR1, CCR3 | SOS1 4244/4885CCR4 1/4885ADRB1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.